| abstract |
A method for treating a patient with gastric cancer is provided. Certain Met fragment peptides are accurately quantified by SRM-mass spectrometry directly in gastric cancer cells recovered from gastric cancer tissue obtained from gastric cancer patients and compared to a reference level. If the Met peptide is below the reference level, the second treatment plan is used to treat the patient, and if the Met peptide is above the reference level, the second treatment plan (eg, the second treatment plan and one or more types) In combination with a Met inhibitor therapeutic agent) can be used to treat patients. |